Susquehanna International Group’s KalVista Pharmaceuticals KALV Stock Holding History

Susquehanna International Group’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$477K	Buy	+23,700	New	+$382K	﹤0.01%	9799
2024 Q4	–	Sell	-12,300	Closed	-$142K	–	12737
2024 Q3	$142K	Sell	12,300 -4,300	-26%	-$54.1K	﹤0.01%	10791
2024 Q2	$196K	Sell	16,600 -25,300	-60%	-$295K	﹤0.01%	10382
2024 Q1	$497K	Sell	41,900 -36,000	-46%	-$480K	﹤0.01%	8525
2023 Q4	$954K	Buy	77,900 +24,200	+45%	+$220K	﹤0.01%	7102
2023 Q3	$517K	Sell	53,700 -52,800	-50%	-$539K	﹤0.01%	8150
2023 Q2	$959K	Buy	+106,500	New	+$982K	﹤0.01%	6775
2022 Q1	–	Sell	-10,400	Closed	-$138K	–	13513
2021 Q4	$138K	Sell	10,400 -89,500	-90%	-$1.42M	﹤0.01%	11886
2021 Q3	$1.74M	Buy	99,900 +6,800	+7%	+$138K	﹤0.01%	6147
2021 Q2	$2.23M	Sell	93,100 -37,500	-29%	-$981K	﹤0.01%	5666
2021 Q1	$3.35M	Sell	130,600 -23,100	-15%	-$607K	﹤0.01%	4721
2020 Q4	$2.92M	Buy	+153,700	New	+$2.64M	﹤0.01%	4354

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Susquehanna International Group's KALV Position: Q1 2026 in Review

Susquehanna International Group reduced its KalVista Pharmaceuticals (KALV) stake by 35% in Q1 2026, selling an estimated $405K and leaving 46,760 shares worth $941K. The position accounts for ﹤0.01% of the portfolio, ranked #8023.

Susquehanna International Group first reported a position in KALV in Q2 2016 and has held it in 24 quarters since. The position peaked at $4.79M in Q3 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Susquehanna International Group held 46,760 shares of KalVista Pharmaceuticals worth $941K as of Q1 2026.
Susquehanna International Group sold 25,135 KalVista Pharmaceuticals shares in Q1 2026, an estimated $405K.
KalVista Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #8023 holding.
Susquehanna International Group first reported a position in KalVista Pharmaceuticals in Q2 2016 and has held it in 24 quarters since.
Susquehanna International Group's KalVista Pharmaceuticals position peaked at $4.79M in Q3 2025.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.